Therefore, a phase II clinical trial (NCT04534114) is focused on the efficacy and safety of 40, 80, and 120 mg of FXI-LICA in inhibiting of thrombosis in patients with end-stage renal disease undergoing regular hemodialysis, with bleeding as a primary endpoint. This evidence concerns the gene F11 and chronic kidney disease.